A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.
Kim
Jin Hun
JH
Yim
Seon Jin
SJ
Nam
Jung Hyun
JH
D019440:Anti-Obesity Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced* / Q000517:prevention & control*; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy*; D000077236:Topiramate; D015430:Weight Gain / Q000187:drug effects*
D019440:Anti-Obesity Agents; D000077236:Topiramate; D001569:Benzodiazepines; D005632:Fructose; D000077152:Olanzapine